Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, characterised by tissue infiltration by foamy CD68+ CD1a− histiocytes.1 The disease has pleomorphic clinical manifestations, including long bones and extraskeletal involvement, and may be life-threatening, particularly when heart and central nervous system are affected.1 ECD histiocytes secrete proinflammatory cytokines2 and carry activating mutations along the RAS-RAF-MEK-ERK protein kinase signalling pathway, most commonly the BRAFV600E oncogenic mutation.3 4 Accordingly, patients with ECD have been treated with cytokine inhibitors, including infliximab,⇓ 5 and, more recently, with the BRAFV600E inhibitor vemurafenib.6 The latter, however, induces sustained but partial clinical responses and recurrences on discontinuation,6 underlining the need for more effective therapeutic strategies. To identify the outcomes downstream constitutive ERK phosphorylation in ECD histiocytes and their response to small molecule-based inhibition, we performed three-dimensional (3D) culture of tissues from three BRAFV600E-mutated ECD patients in the RCCS bioreactor7 (and online supplementary methods) in the presence/absence of vemurafenib or infliximab, used as control.

Villa, A., Belloni, D., Vergani, B., Cenci, S., Cavalli, G., Biavasco, R., et al. (2019). 3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. ANNALS OF THE RHEUMATIC DISEASES, 78(6), 862-864 [10.1136/annrheumdis-2018-214432].

3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target

Vergani, B;
2019

Abstract

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, characterised by tissue infiltration by foamy CD68+ CD1a− histiocytes.1 The disease has pleomorphic clinical manifestations, including long bones and extraskeletal involvement, and may be life-threatening, particularly when heart and central nervous system are affected.1 ECD histiocytes secrete proinflammatory cytokines2 and carry activating mutations along the RAS-RAF-MEK-ERK protein kinase signalling pathway, most commonly the BRAFV600E oncogenic mutation.3 4 Accordingly, patients with ECD have been treated with cytokine inhibitors, including infliximab,⇓ 5 and, more recently, with the BRAFV600E inhibitor vemurafenib.6 The latter, however, induces sustained but partial clinical responses and recurrences on discontinuation,6 underlining the need for more effective therapeutic strategies. To identify the outcomes downstream constitutive ERK phosphorylation in ECD histiocytes and their response to small molecule-based inhibition, we performed three-dimensional (3D) culture of tissues from three BRAFV600E-mutated ECD patients in the RCCS bioreactor7 (and online supplementary methods) in the presence/absence of vemurafenib or infliximab, used as control.
Articolo in rivista - Articolo scientifico
Rheumatology; Immunology and Allergy; Immunology; Biochemistry, Genetics and Molecular Biology (all)
English
2019
78
6
862
864
none
Villa, A., Belloni, D., Vergani, B., Cenci, S., Cavalli, G., Biavasco, R., et al. (2019). 3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. ANNALS OF THE RHEUMATIC DISEASES, 78(6), 862-864 [10.1136/annrheumdis-2018-214432].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/223602
Citazioni
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
Social impact